Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Cambridge, USA
Aaron Goldman working as Director of Drug Resistance, Harvard Medical School, Cancer Immunology, DFCI/HCC, USA. His research is focused on understanding the diversity of cells that comprise cancer, collectively termed ‘intratumor heterogeneity’, and its role in therapy failure using interdisciplinary strategies that interrogate evolutionary biology. He has junior faculty position at Harvard Medical School and MIT Division of Health Sciences and Technology. Aaron Goldman have been supported by the North East Spin Odyssey Foundation, American Cancer Society, Breast Cancer Alliance, and the Biomedical Research Institute to develop cross-collaborative projects that resulted in multiple international patents.